Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | June 05, 2025 | June 09, 2025 |
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | Director | May 21, 2025 | May 23, 2025 |
| IMMUNE DESIGN CORP.IMDZ · Entity 158527 | Director | April 02, 2019 | April 04, 2019 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | September 20, 2017 | September 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.81 · Expires 2035-06-05 | Direct | 3,500 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 3,500 · Balance 3,500 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders.
Faeth Therapeutics, Inc.
Report date May 21, 2025 · Filed May 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2035-05-20 | Direct | 19,000 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 19,000 · Balance 19,000 F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
IMMUNE DESIGN CORP.
Report date April 02, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding.
F2: Not Applicable.
SANGAMO THERAPEUTICS, INC
Report date September 20, 2017 · Filed September 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 800 |
Ending reported balance
After 2017-09-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-09-20 · Exercise / conversion · Acquired 31,000 · Balance 31,800 Row 2 · 2017-09-20 · Sale · Disposed 31,000 · Balance 800 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.55, inclusive. The Reporting Person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05 · Expires 2020-04-15 | Direct | 0 |
Reported balance
After 2017-09-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-09-20 · Exercise / conversion · Disposed 31,000 · Balance 0 F2: The shares underlying the stock option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.55, inclusive. The Reporting Person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F2: The shares underlying the stock option are fully vested and exercisable.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 24, 2020
Section 16 reporting ended · disclosed 2020-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-06-05 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Disposition to issuer · Disposed 18,275 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-20 · Disposition to issuer · Disposed 8,620 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.82 · Expires 2026-06-20 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.01 · Expires 2027-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2029-06-03 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
FIVE PRIME THERAPEUTICS, INC.
Report date April 05, 2021 · Filed April 19, 2021
Section 16 reporting ended · disclosed 2021-04-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-04-05 transaction · row 1
1 source rowRow 1 · 2021-04-05 · Gift · Disposed 10,000 · Balance 0 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.65 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-16 · Disposition to issuer · Disposed 16,600 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.15 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-04-16 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.80 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.27 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-04-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-04-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-04-16 · Disposition to issuer · Disposed 34,451 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-04-16 · Disposition to issuer · Disposed 46,939 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.23 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-04-16 · Disposition to issuer · Disposed 50,367 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-04-16 · Disposition to issuer · Disposed 49,552 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.31 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-04-16 · Disposition to issuer · Disposed 40,868 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.23 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-04-16 · Disposition to issuer · Disposed 37,998 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-04-16 · Disposition to issuer · Disposed 52,408 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-04-16 · Disposition to issuer · Disposed 27,769 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.
F2: Not applicable.
PFIZER INC
Report date March 31, 2010 · Filed April 01, 2010
Section 16 reporting ended · disclosed 2010-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 10,415 |
Reported balance
After 2010-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2010-03-31 · Grant · Acquired 144 · Balance 10,415 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2017 Filed Jan 3, 2017 18:32 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | SaleCommon Stock | 500 | $51.07 | $25,535.00 |
DisclosureSEC source: 0001209191-17-000448 · doc4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016. Read SEC document |
| January 03, 2017 Filed Jan 3, 2017 18:32 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Exercise / conversionCommon Stock | 500 | $11.65 | $5,825.00 |
DisclosureSEC source: 0001209191-17-000448 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2016 Filed Dec 16, 2016 16:50 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 125 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003832 · primarydocument.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,775 Underlying: Common Stock · 125 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/36th of the shares underlying the option vest each month from the vesting commencement date of 7/25/2014, subject to the reporting person's continuous status as a Service Provider on the applicable vesting date. Read SEC document |
| December 16, 2016 Filed Dec 16, 2016 16:50 UTC | Dermira, Inc. DERM · Entity 11896 | SaleCommon Stock | 125 | $32.00 | $4,000.00 |
DisclosureSEC source: 0001562180-16-003832 · primarydocument.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 16, 2016 Filed Dec 16, 2016 16:50 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 125 | $16.00 | $2,000.00 |
DisclosureSEC source: 0001562180-16-003832 · primarydocument.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 17:24 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Exercise / conversionStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $11.65 | $0.00 |
DisclosureSEC source: 0001209191-16-153112 · doc4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 500 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest at a rate of one-third per year on each anniversary of October 1, 2014. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 17:24 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | SaleCommon Stock | 500 | $57.72 | $28,860.00 |
DisclosureSEC source: 0001209191-16-153112 · doc4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 17:24 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Exercise / conversionCommon Stock | 500 | $11.65 | $5,825.00 |
DisclosureSEC source: 0001209191-16-153112 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 17:06 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 375 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003661 · primarydocument.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 375 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/36th of the shares underlying the option vest each month from the vesting commencement date of 7/25/2014, subject to the reporting person's continuous status as a Service Provider on the applicable vesting date. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 17:06 UTC | Dermira, Inc. DERM · Entity 11896 | SaleCommon Stock | 375 | $32.00 | $12,000.00 |
DisclosureSEC source: 0001562180-16-003661 · primarydocument.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 17:06 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 375 | $16.00 | $6,000.00 |
DisclosureSEC source: 0001562180-16-003661 · primarydocument.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 16:02 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003451 · primarydocument.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,275 Underlying: Common Stock · 500 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/36th of the shares underlying the option vest each month from the vesting commencement date of 7/25/2014, subject to the reporting person's continuous status as a Service Provider on the applicable vesting date. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 16:02 UTC | Dermira, Inc. DERM · Entity 11896 | SaleCommon Stock | 500 | $32.30 | $16,150.00 |
DisclosureSEC source: 0001562180-16-003451 · primarydocument.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 16:02 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 500 | $16.00 | $8,000.00 |
DisclosureSEC source: 0001562180-16-003451 · primarydocument.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 14:48 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Exercise / conversionStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $11.65 | $0.00 |
DisclosureSEC source: 0001209191-16-147814 · doc4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 500 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest at a rate of one-third per year on each anniversary of October 1, 2014. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 14:48 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | SaleCommon Stock | 500 | $48.67 | $24,335.00 |
DisclosureSEC source: 0001209191-16-147814 · doc4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 14:48 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Exercise / conversionCommon Stock | 500 | $11.65 | $5,825.00 |
DisclosureSEC source: 0001209191-16-147814 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 12:55 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Exercise / conversionStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $11.65 | $0.00 |
DisclosureSEC source: 0001209191-16-143872 · doc4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 500 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest at a rate of one-third per year on each anniversary of October 1, 2014. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 12:55 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | SaleCommon Stock | 500 | $52.00 | $26,000.00 |
DisclosureSEC source: 0001209191-16-143872 · doc4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 12:55 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Exercise / conversionCommon Stock | 500 | $11.65 | $5,825.00 |
DisclosureSEC source: 0001209191-16-143872 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 18:03 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003217 · primarydocument.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,775 Underlying: Common Stock · 500 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/36th of the shares underlying the option vest each month from the vesting commencement date of 7/25/2014, subject to the reporting person's continuous status as a Service Provider on the applicable vesting date. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 18:03 UTC | Dermira, Inc. DERM · Entity 11896 | SaleCommon Stock | 500 | $34.25 | $17,125.00 |
DisclosureSEC source: 0001562180-16-003217 · primarydocument.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 18:03 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 500 | $16.00 | $8,000.00 |
DisclosureSEC source: 0001562180-16-003217 · primarydocument.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2010 Filed Apr 1, 2010 22:43 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 144 | $17.15 | $2,469.60 |
DisclosureSEC source: 0001225208-10-009471 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,415 Underlying: Common Stock · 144 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2010 Filed Mar 17, 2010 13:23 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 3,171 | $17.26 | $54,731.46 |
DisclosureSEC source: 0001225208-10-008377 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,271 Underlying: Common Stock · 3,171 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 25, 2010 Filed Mar 2, 2010 02:02 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 13,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-006404 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,798 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| December 31, 2009 Filed Jan 4, 2010 21:08 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 137 | $18.19 Strike: $0.00 | $2,492.03 |
DisclosureSEC source: 0001225208-10-000237 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,028 Underlying: Common Stock · 137 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2009 Filed Dec 16, 2009 22:08 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 134 | $18.29 Strike: $0.00 | $2,450.86 |
DisclosureSEC source: 0001225208-09-024597 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,891 Underlying: Common Stock · 134 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 30, 2009 Filed Dec 1, 2009 21:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 134 | $18.17 Strike: $0.00 | $2,434.78 |
DisclosureSEC source: 0001225208-09-023559 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,757 Underlying: Common Stock · 134 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 13, 2009 Filed Nov 17, 2009 00:49 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 199 | $17.59 Strike: $0.00 | $3,500.41 |
DisclosureSEC source: 0001225208-09-022356 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,623 Underlying: Common Stock · 199 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 30, 2009 Filed Nov 3, 2009 21:37 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 145 | $17.03 Strike: $0.00 | $2,469.35 |
DisclosureSEC source: 0001225208-09-021516 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,424 Underlying: Common Stock · 145 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2009 Filed Oct 16, 2009 21:09 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 139 | $17.66 | $2,454.74 |
DisclosureSEC source: 0000078003-09-000225 · primary_doc.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,279 Underlying: Common Stock · 139 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2009 Filed Oct 1, 2009 17:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 150 | $16.55 | $2,482.50 |
DisclosureSEC source: 0000078003-09-000212 · primary_doc.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,140 Underlying: Common Stock · 150 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2009 Filed Sep 16, 2009 23:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 155 | $16.21 | $2,512.55 |
DisclosureSEC source: 0000078003-09-000197 · primary_doc.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,990 Underlying: Common Stock · 155 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2009 Filed Sep 1, 2009 22:10 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 143 | $16.70 | $2,388.10 |
DisclosureSEC source: 0000078003-09-000187 · primary_doc.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,835 Underlying: Common Stock · 143 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 14, 2009 Filed Aug 18, 2009 15:31 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 213 | $15.77 | $3,359.01 |
DisclosureSEC source: 0000078003-09-000177 · rin2120.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,692 Underlying: Common Stock · 213 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2009 Filed Aug 4, 2009 15:10 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 155 | $15.93 | $2,469.15 |
DisclosureSEC source: 0000078003-09-000169 · rin2111.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,479 Underlying: Common Stock · 155 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2009 Filed Jul 16, 2009 19:56 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 165 | $15.02 | $2,478.30 |
DisclosureSEC source: 0000078003-09-000157 · rin2103.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,324 Underlying: Common Stock · 165 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2009 Filed Jul 1, 2009 20:24 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 163 | $15.00 | $2,445.00 |
DisclosureSEC source: 0000078003-09-000142 · rin2086.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,159 Underlying: Common Stock · 163 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2009 Filed Jun 16, 2009 19:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 177 | $14.13 | $2,501.01 |
DisclosureSEC source: 0000078003-09-000130 · rin2068.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,996 Underlying: Common Stock · 177 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 29, 2009 Filed Jun 2, 2009 13:58 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 163 | $15.19 | $2,475.97 |
DisclosureSEC source: 0000078003-09-000119 · rin2055.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,819 Underlying: Common Stock · 163 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2009 Filed May 18, 2009 20:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 211 | $15.01 | $3,167.11 |
DisclosureSEC source: 0000078003-09-000109 · rin2044.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,656 Underlying: Common Stock · 211 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2009 Filed May 1, 2009 18:01 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 185 | $13.36 | $2,471.60 |
DisclosureSEC source: 0000078003-09-000099 · rin2034.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,445 Underlying: Common Stock · 185 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2009 Filed Apr 16, 2009 21:21 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 180 | $13.86 | $2,494.80 |
DisclosureSEC source: 0000078003-09-000076 · rin2012.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,260 Underlying: Common Stock · 180 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 31, 2009 Filed Apr 1, 2009 20:06 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 187 | $13.62 | $2,546.94 |
DisclosureSEC source: 0000078003-09-000063 · rin2003.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,080 Underlying: Common Stock · 187 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 13, 2009 Filed Mar 16, 2009 20:50 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 2,211 | $14.54 | $32,147.94 |
DisclosureSEC source: 0000078003-09-000050 · rin1987.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,893 Underlying: Common Stock · 2,211 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:26 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 96,393 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000078003-09-000037 · rin1974.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,393 Underlying: Common Stock · 96,393 shares Expires 2014-02-26 F2 · derivative.exercise_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant F2 · derivative.expiration_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:26 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 44,894 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-09-000037 · rin1974.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,283 F1 · shares: The reported transaction constitutes the grant of restricted stock units. Read SEC document |
| December 31, 2008 Filed Jan 5, 2009 12:58 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 140 | $17.71 | $2,479.40 |
DisclosureSEC source: 0000078003-09-000010 · rin1951.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,640 Underlying: Common Stock · 140 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2008 Filed Dec 16, 2008 23:51 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 149 | $16.63 | $2,477.87 |
DisclosureSEC source: 0000078003-08-000317 · rin1940.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 149 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.